Clinical Trial Update: CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL [Phase 2]

View source ↗

Summary

Phase 2 trial update on CART19 therapy for adults with minimal residual disease during upfront treatment for acute lymphoblastic leukemia; study terminated with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CART19 (CD19-directed chimeric antigen receptor T cells)

Snippet

Sponsor: University of Pennsylvania | Conditions: Leukemia, Acute Lymphoblastic | Phase 2 | Status: TERMINATED | Results posted: 2020-02-05